Sector News

Gilead banks $10B, stirring fresh buzz about a blockbuster buyout

September 11, 2015
Life sciences

Four years ago, when Gilead bought Pharmasset for $11 billion in cash, there was a considerable amount of hooting on Twitter–and fretting among the analysts–about the huge gamble. That deal netted the company’s franchise drug for hepatitis C, though, which immediately became a megablockbuster of historic proportions once it was approved and rolled out around the world.

In the second quarter, Gilead racked up close to $5 billion in hep C revenue from Sovaldi and Harvoni. And nobody hoots about the price execs paid anymore.

So it’s no wonder then that when Gilead laid out the terms for raising $10 billion yesterday, on top of the blockbuster money it earns on HIV and hepatitis C, the move immediately stirred fresh buzz about what Gilead was going to buy next, and for how much.

Gilead’s last quarterly call with analysts was highlighted by CEO John Martin’s flirtatious remark that the company is “taking suggestions” about what it should buy. And with no hard hit list to contemplate, analysts have suggested the likes of Vertex, Incyte, BioMarin, Medivation and Alexion.

President John Milligan, though, essentially said that everything is on the table.

“As you suggested we could contemplate small deals, we could contemplate larger, perhaps even transformative deals,” Milligan told analysts in July. “And we’re in a position of strength so we could be fairly selective in terms of the things that we like to do and take our time to make sure that those things that we do choose to do we can execute on them fairly effectively, bring new products to market and continue to grow our top line revenue and EPS and so we’ll take all those.”

Gilead doesn’t reveal much to anyone about its internal planning process. Among big biotechs, it has the most closely guarded approach to dealmaking. So it was no surprise that the release mentioned that the money was intended for “general corporate purposes”–which is the way Gilead says “we’ll tell you when we’re ready.”

As The Wall Street Journal’s Charley Grant noted, “investors can hope that Gilead might be finally getting around to making a large acquisition. Shareholders have clamored for a big deal as Gilead’s hepatitis C franchise matures, while management has remained coy about its intentions.”

In this M&A environment, though, the right deal will be greeted by a cheering section filled with Wall Street analysts.

By John Carroll

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.